1Najafi F, Jamrozik K & Dobson AJ (2009) Understanding the ‘epidemic of heart failure’: a systematic review of trends in determinants of heart failure. Eur J Heart Fail 11, 472–479.
2Bucher HC, Hengstler P, Schindler C, et al. (2002) n-3 Polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 112, 298–304.
3Mozaffarian D, Ascherio A, Hu FB, et al. (2005) Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Circulation 111, 157–164.
4McLennan PL, Abeywardena MY & Charnock JS (1988) Dietary fish oil prevents ventricular fibrillation following coronary artery occlusion and reperfusion. Am Heart J 116, 709–717.
5Siscovick DS, Raghunathan TE, King I, et al. (1995) Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 274, 1363–1367.
6Marchioli R, Barzi F, Bomba E, et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the GISSI-Prevenzione. Circulation 105, 1897–1903.
7Mozaffarian D, Bryson CL, Lemaitre RN, et al. (2005) Fish intake and risk of incident heart failure. J Am Coll Cardiol 45, 2015–2021.
8Valagussa F, Franzosi MG, Geraci E, et al. (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354, 447–455.
9Nordoy A, Marchioli R, Arnesen H, et al. (2001) n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids 36, S127–S129.
10Burr ML, Fehily AM, Gilbert JF, et al. (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet ii, 757–761.
11al Makdessi S, Brandle M, Ehrt M, et al. (1995) Myocardial protection by ischemic preconditioning: the influence of the composition of myocardial phospholipids. Mol Cell Biochem 145, 69–73.
12Pepe S & McLennan PL (1996) Dietary fish oil confers direct antiarrhythmic properties on the myocardium of rats. J Nutr 126, 34–42.
13Pepe S & McLennan PL (2002) Cardiac membrane fatty acid composition modulates myocardial oxygen consumption and post-ischemic recovery of contractile function. Circulation 105, 2303–2308.
14McLennan PL & Abeywardena MY (2005) Membrane basis for fish oil effects on the heart: linking natural hibernators to prevention of human sudden cardiac death. J Memb Biol 206, 85–102.
15McLennan P, Howe P, Abeywardena M, et al. (1996) The cardiovascular protective role of docosahexaenoic acid. Eur J Pharmacol 300, 83–89.
16Abdukeyum GG, Owen AJ & McLennan PL (2008) Dietary (n-3) long-chain polyunsaturated fatty acids inhibit ischemia and reperfusion arrhythmias and infarction in rat heart not enhanced by ischemic preconditioning. J Nutr 138, 1902–1909.
17Demaison L & Grynberg A (1994) Cellular and mitochondrial energy metabolism in the stunned myocardium. Basic Res Cardiol 89, 293–307.
18Mettauer B, Zoll J, Garnier A, et al. (2006) Heart failure: a model of cardiac and skeletal muscle energetic failure. Pflug Arch 452, 653–666.
19Ormerod JOM, Ashrafian H & Frenneaux MP (2008) Impaired energetics in heart failure – a new therapeutic target. Pharmacol Ther 119, 264–274.
20Reibel DK, O'Rourke B, Foster KA, et al. (1986) Altered phospholipid-metabolism in the pressure-overload hypertrophied hearts. Am J Physiol 250, H1–H6.
21Duda MK, O'Shea KM, Lei B, et al. (2007) Dietary supplementation with omega-3 PUFA increases adiponectin and attenuates ventricular remodeling and dysfunction with pressure overload. Cardiovasc Res 76, 303–310.
22Siddiqui RA, Shaikh SR, Kovacs R, et al. (2004) Inhibition of phenylephrine-induced cardiac hypertrophy by docosahexaenoic acid. J Cell Biochem 92, 1141–1159.
23Slee EL, McLennan PL, Owen AJ, et al. (2010) Low dietary fish oil threshold for myocardial membrane n-3 PUFA enrichment independent of n-6 PUFA intake in rats. J Lipid Res 51, 1841–1848.
24Duda MK, O'Shea KM, Tintinu A, et al. (2009) Fish oil, but not flaxseed oil, decreases inflammation and prevents pressure overload-induced cardiac dysfunction. Cardiovasc Res 81, 319–327.
25Takahashi R, Okumura K, Asai T, et al. (2005) Dietary fish oil attenuates cardiac hypertrophy in lipotoxic cardiomyopathy due to systemic carnitine deficiency. Cardiovasc Res 68, 213–223.
26Traverse JH, Chen Y, Crampton M, et al. (2001) Increased extravascular forces limit endothelium-dependent and -independent coronary vasodilation in congestive heart failure. Cardiovasc Res 52, 454–461.
27Siddiqui RA, Harvey KA & Zaloga GP (2008) Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J Nutr Biochem 19, 417–437.
28Pepe S, Tsuchiya N, Lakatta EG, et al. (1999) PUFA and aging modulate cardiac mitochondrial membrane lipid composition and Ca2+ activation of PDH. Am J Physiol 276, H149–H158.
29Hallaq H, Sellmayer A, Smith TW, et al. (1990) Protective effect of eicosapentaenoic acid on ouabain toxicity in neonatal rat cardiac myocytes. Proc Natl Acad Sci 87, 7834–7838.
30Leifert WR, Dorian CL, Jahangiri A, et al. (2001) Dietary fish oil prevents asynchronous contractility and alters Ca2+ handling in adult rat cardiomyocytes. J Nutr Biochem 12, 365–376.
31McLennan PL (2001) Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 36, S111–S114.
32Sexton PT, Sinclair AJ, O'Dea K, et al. (1995) The relationship between linoleic acid level in serum, adipose tissue and myocardium in humans. Asia Pacific J Clin Nutr 4, 314–318.
33Calder PC (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids 77, 327–335.
34Mozaffarian D, Geelen A, Brouwer IA, et al. (2005) Effect of fish oil on heart rate in humans – a meta-analysis of randomized controlled trials. Circulation 112, 1945–1952.
35Yokoyama M, Origasa H, Matsuzaki M, et al. (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis. Lancet 369, 1090–1098.
36Abeywardena MY & Charnock JS (1995) Dietary lipid modification of myocardial eicosanoids following ischemia and reperfusion in the rat. Lipids 30, 1151–1156.
37Abeywardena MY, McLennan PL & Charnock JS (1991) Changes in myocardial eicosanoid production following long-term dietary lipid supplementation in rats. Am J Clin Nutr 53, 1039S–1041S.
38Novak F, Kolar F, Hamplova B, et al. (2009) Myocardial phospholipid remodeling under different types of load imposed during early postnatal development. Physiol Res 58, S13–S32.
39Gudbjarnason S, Benediktsdottir VE & Skuladottir G (1989) Effects of n-3 polyunsaturated fatty acids on coronary heart disease. Bibliotheca Nutritio et Dieta 43, 1–12.
40Nikolaidis LA, Trumble D, Hentosz T, et al. (2004) Catecholamines restore myocardial contractility in dilated cardiomyopathy at the expense of increased coronary blood flow and myocardial oxygen consumption (MVO2 cost of catecholamines in heart failure). Eur J Heart Fail 6, 409–419.
41Katz AM (1986) Potential deleterious effects of inotropic agents in the therapy of chronic heart-failure. Circulation 73, 184–190.
42Lubic SP, Giacomini KM & Giacomini JC (1995) The effects of modulation of calcium influx through the voltage-sensitive calcium-channel on cardiomyocyte hypertrophy. J Mol Cell Cardiol 27, 917–925.
43Eichhorn EJ & Bristow MR (1996) Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation 94, 2285–2296.
44Kim S, Yoshiyama M, Izumi Y, et al. (2001) Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. Circulation 103, 148–154.
45Nagatsu M, Spinale FG, Koide M, et al. (2000) Bradycardia and the role of β-blockade in the amelioration of left ventricular dysfunction. Circulation 101, 653–659.
46Reibel DK, Holahan MA & Hock CE (1988) Effects of dietary fish oil on cardiac responsiveness to adrenoceptor stimulation. Am J Physiol 254, H494–H499.
47Levitan EB, Wolk A & Mittleman MA (2009) Fish consumption, marine omega-3 fatty acids, and incidence of heart failure: a population-based prospective study of middle-aged and elderly men. Eur Heart J 30, 1495–1500.
48Tavazzi L, Maggioni AP, Marchioli R, et al. (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1223–1230.
49Ghio S, Scelsi L, Latini R, et al. (2010) Effects of n-3 polyunsaturated fatty acids and of rosuvastatin on left ventricular function in chronic heart failure: a substudy of GISSI-HF trial. Eur J Heart Fail 12, 1345–1353.
50McLennan PL, Owen AJ, Slee EL, et al. (2007) Myocardial function, ischaemia and n-3 polyunsaturated fatty acids: a membrane basis. J Cardiovasc Med 8, Suppl. 1, S15–S18.
51Mozaffarian D & Rimm EB (2006) Fish intake, contaminants, and human health – evaluating the risks and the benefits. JAMA 296, 1885–1899.
52Owen AJ, Peter-Przyborowska BA, Hoy AJ, et al. (2004) Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition. Lipids 39, 955–961.
53Pepe S & McLennan P (2007) (n-3) Long chain PUFA dose-dependently increase oxygen utilization efficiency and inhibit arrhythmias after saturated fat feeding in rats. J Nutr 137, 2377–2383.